In this special report, insurance carriers and benefits advisors agree that the time has come to reassess corporate objectives to protect the sustainability of drug plans, which will increasingly be relied upon to provide coverage for higher-cost specialty drugs.

Get practical suggestions on how to weigh the corporate philosophy for drug benefits against the capacity to tolerate risk, and the implications for current—and untapped—drug plan management strategies across all drug claims.

 

Telus